Rao et al. [79] investigated the anti-angiogenic effect of MPO250, a multi-domain designed ankyrin repeat protein (DARPin) drug which binds simultaneously VEGF and HGF, in MM. Here, VEGFA is linked to Miyoshi myopathy.